ProQR Therapeutics (NASDAQ:PRQR) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in a research report released on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $8.00 price objective on the biopharmaceutical company's stock. Cantor Fitzgerald also issued estimates for ProQR Therapeutics' FY2025 earnings at ($0.39) EPS.

Several other brokerages also recently weighed in on PRQR. Oppenheimer began coverage on ProQR Therapeutics in a research note on Friday, January 10th. They set an "outperform" rating and a $15.00 target price for the company. HC Wainwright increased their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Friday, March 14th. Chardan Capital reaffirmed a "buy" rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a report on Friday, March 14th. Evercore ISI started coverage on ProQR Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $5.00 price target for the company. Finally, Citigroup upgraded shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective on the stock in a research note on Monday, March 10th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, ProQR Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $8.75.

ProQR Therapeutics Trading Up 3.6 %

Shares of PRQR traded up $0.06 during mid-day trading on Tuesday, reaching $1.72. The company had a trading volume of 491,691 shares, compared to its average volume of 603,874. The stock has a market cap of $180.97 million, a price-to-earnings ratio of -5.38 and a beta of 0.25. The firm has a fifty day simple moving average of $1.56 and a 200-day simple moving average of $2.49. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $4.62.

Institutional Investors Weigh In On ProQR Therapeutics

A number of large investors have recently bought and sold shares of PRQR. Affinity Asset Advisors LLC bought a new stake in ProQR Therapeutics during the fourth quarter worth $7,486,000. M&T Bank Corp acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth about $330,000. XTX Topco Ltd bought a new stake in shares of ProQR Therapeutics in the 4th quarter valued at about $163,000. Altium Capital Management LLC acquired a new stake in ProQR Therapeutics in the 4th quarter valued at about $1,524,000. Finally, Adage Capital Partners GP L.L.C. grew its holdings in ProQR Therapeutics by 164.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company's stock worth $25,446,000 after purchasing an additional 5,976,813 shares during the period. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).